BD is executing the Life Sciences segment separation announced in 2024, leaving a focused medical products and interventional business. Alaris pump return to market continues, and pharma systems (prefilled syringes for GLP-1s) is a structural tailwind. Margin recovery is steady but slower than peers. Capital allocation post-separation will determine multiple expansion.
Thesis reviewed May 29, 2026
Becton Dickinson and Company is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →🏥Healthcare33NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| CVS | CVS Health Corporation | 40 | +15% | ↓3% | AVOID |
| HCA | HCA Healthcare Inc. | 40 | +9% | ↓3% | EARLY |
| UNH | UnitedHealth Group Inc. | 37 | +16% | ↓3% | AVOID |
| TMO | Thermo Fisher Scientific Inc. | 37 | +11% | ↓3% | EARLY |
| CI | The Cigna Group | 37 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 37 | +7% | ↓3% | NEUTRAL |
| TEVA | Teva Pharmaceutical Industries Ltd. | 37 | +9% | ↓3% | NEUTRAL |
Investors who hold BDX may also have indirect exposure through these country funds.
BD pharma systems demand for GLP-1 injectables exceeds capacity
BD announces life sciences separation timeline
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $1k–$15k | Mar 27, 26 | ||
| Thomas H. KeanNJ | Buy | $1k–$15k | May 21, 26 | ||
| Kevin HernOK | R | Buy | $15k–$50k | Mar 17, 26 | -4.8% |
| John JamesMI | R | Buy | $1k–$15k | Sep 4, 24 | -16.6% |
| John JamesMI | R | Buy | $1k–$15k | Nov 10, 23 | -19.9% |
| Thomas H. KeanNJ | R | Buy | $1k–$15k | May 24, 24 | -17.0% |